Gujarat Terce Laboratories Ltd Stock Price Today (NSE: GUJTERC)
Fundamental Score
Gujarat Terce Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Gujarat Terce Laboratories Ltd share price today is ₹42.98, up +4.70% on NSE/BSE as of 7 August 2026. Gujarat Terce Laboratories Ltd (GUJTERC) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹25.85 (Cr). The 52-week high for GUJTERC share price is ₹59.78 and the 52-week low is ₹29.00. At a P/E ratio of 10.38x, GUJTERC is currently trading below its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 30.72% and a debt-to-equity ratio of 0.13.
Gujarat Terce Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Gujarat Terce Laboratories Ltd share price chart: 7.55% return over the past month. 52-week high ₹59.78, 52-week low ₹29.00.
Gujarat Terce Laboratories Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹42.20 | ₹43.45 | ₹41.50 | ₹42.98 | 13.37K (Cr) | |
| ₹43.00 | ₹43.95 | ₹41.05 | ₹41.05 | 10.28K (Cr) | |
| ₹43.00 | ₹43.00 | ₹40.60 | ₹41.95 | 6.44K (Cr) | |
| ₹40.83 | ₹42.89 | ₹40.49 | ₹41.34 | 8.09K (Cr) | |
| ₹40.95 | ₹41.50 | ₹38.00 | ₹40.83 | 24.38K (Cr) | |
| ₹38.00 | ₹39.19 | ₹36.51 | ₹37.91 | 3.89K (Cr) | |
| ₹38.00 | ₹38.00 | ₹36.25 | ₹36.25 | 3.34K (Cr) | |
| ₹34.30 | ₹37.88 | ₹34.30 | ₹37.88 | 15.03K (Cr) | |
| ₹34.00 | ₹34.90 | ₹33.30 | ₹34.30 | 1.20K (Cr) | |
| ₹35.00 | ₹36.00 | ₹34.15 | ₹34.90 | 7.93K (Cr) |
Gujarat Terce Laboratories Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹40.95 | ₹43.95 | ₹38.00 | ₹42.98 | +4.96% | |
| ₹36.00 | ₹39.19 | ₹32.11 | ₹37.91 | +5.31% | |
| ₹36.00 | ₹39.60 | ₹30.12 | ₹35.79 | -0.58% | |
| ₹39.34 | ₹39.34 | ₹33.06 | ₹34.76 | -11.64% | |
| ₹33.80 | ₹42.00 | ₹30.51 | ₹37.61 | +11.27% | |
| ₹38.36 | ₹41.90 | ₹29.00 | ₹30.90 | -19.45% | |
| ₹47.50 | ₹47.50 | ₹37.20 | ₹38.36 | -19.24% | |
| ₹45.99 | ₹50.00 | ₹40.00 | ₹46.00 | +0.02% | |
| ₹46.89 | ₹49.95 | ₹42.01 | ₹43.50 | -7.23% | |
| ₹46.00 | ₹49.40 | ₹41.50 | ₹45.18 | -1.78% | |
| ₹46.35 | ₹59.78 | ₹42.00 | ₹45.75 | -1.29% | |
| ₹40.75 | ₹48.00 | ₹37.20 | ₹45.49 | +11.63% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Gujarat Terce Laboratories Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Gujarat Terce Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of GUJTERC across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Strong Return on Equity (30.72%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (39.78%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Attractive Valuation (P/E: 10.38 vs Industry: 34.89)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Robust Profit Growth (107.08%)
Observation: Strong year-over-year profit expansion demonstrates business momentum.
Analysis: Profit growth >20% indicates effective execution and market opportunity capture.
Consistent Growth Track Record (13.52% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (24.68% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (25.10% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.13)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (20.39x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Margin Pressure Concerns (3.38%)
Observation: Operating margins are below industry standards.
Analysis: OPM <5% may indicate pricing pressures or cost management challenges.
Revenue Contraction (-7.47%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
No Dividend Distribution
Observation: Company does not currently pay dividends to shareholders.
Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.
Gujarat Terce Laboratories Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Gujarat Terce Laboratories Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Gujarat Terce Laboratories LtdGujarat Terce L...Selected✓ GUJTERC • 524314 | 64.1/100 | ₹42.98₹43 | ₹25.85₹25.85 | 10.38Average 10.4 Average | 30.72%Excellent 30.72% Excellent | 39.78%Excellent 39.78% Excellent | 0.13Excellent 0.1 Excellent | 25.10%Excellent 25.10% Excellent | 13.52%Good 13.52% Good | 0.00% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LtdTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Torrent Pharmaceuticals Ltd share price169902.02 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
Gujarat Terce Laboratories Ltd Quarterly Performance
Latest quarterly metrics for GUJTERC — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
-7.47%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
107.08%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.52%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
25.10%
Compounded annual net profit growth over 5 years
Gujarat Terce Laboratories Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for GUJTERC — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Gujarat Terce Laboratories Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Gujarat Terce Laboratories Ltd (GUJTERC) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Gujarat Terce Laboratories Ltd
About GUJTERC (Gujarat Terce Laboratories Ltd)
Gujarat Terce Laboratories Ltd is a dynamic pharmaceutical company committed to improving global health through the development, production, and distribution of high-quality medici...nes. With a strong emphasis on research and innovation, GUJTERC strives to create effective therapeutic solutions that address a wide range of medical needs. Leveraging state-of-the-art manufacturing facilities and adhering to stringent international quality standards, the company ensures that its products meet the highest benchmarks of safety and efficacy. Driven by a passion for patient well-being, GUJTERC actively invests in cutting-edge technologies and skilled personnel, fostering a culture of continuous improvement and scientific excellence. GUJTERC's diverse product portfolio caters to various therapeutic segments, providing accessible and affordable healthcare options to patients worldwide. From essential antibiotics and respiratory medications to specialized nutraceuticals and gynecological treatments, the company offers a comprehensive range of pharmaceutical solutions. Committed to innovation, GUJTERC also explores the synergy between modern medicine and traditional healing practices, integrating Ayurvedic principles into its product development process. Through strategic partnerships and collaborations, the company expands its reach and impact, delivering life-changing medicines to communities in need. GUJTERC's unwavering commitment to quality, affordability, and innovation positions it as a trusted partner in healthcare. Beyond its commitment to pharmaceutical excellence, Gujarat Terce Laboratories Ltd is deeply rooted in ethical business practices and corporate social responsibility. The company actively supports community development initiatives, focusing on healthcare access, education, and environmental sustainability. Through transparent operations and a dedication to environmental stewardship, GUJTERC seeks to create long-term value for its stakeholders and contribute to a healthier, more sustainable future. By upholding the highest ethical standards and prioritizing the well-being of both patients and communities, GUJTERC strives to be a responsible and respected leader in the global pharmaceutical industry.
Company Details
Key Leadership
GUJTERC Share Price: Frequently Asked Questions
What is the current share price of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd (GUJTERC) trades at ₹42.98 on NSE and BSE. Market cap ₹25.85 (Cr). Educational data only.
What is the P/E ratio of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd has a P/E of 10.38x vs industry average 34.89x.
What is the Bull Run score for Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd has a Bull Run score of 64.1/100 based on 25+ financial parameters.
Does Gujarat Terce Laboratories Ltd pay dividends?
Gujarat Terce Laboratories Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.
What is the ROE of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd has ROE of 30.72%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Gujarat Terce Laboratories Ltd?
Gujarat Terce Laboratories Ltd has debt-to-equity of 0.13.
Is Gujarat Terce Laboratories Ltd a good investment?
Bull Run gives Gujarat Terce Laboratories Ltd a score of 64.1/100. This is not investment advice — consult a SEBI-registered advisor.